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Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia. In this study, we investigated the antipsychotic profiles of (2S)-5-methyl-2-{[4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenoxy]methyl}-2,3-dihydroimidazo [2,1-b] [1, 3] oxazole-6-carboxamide (TASP0443294), a newly synthesized positive allosteric modulator of the mGlu2 receptor. TASP0443294 potentiated the response of human mGlu2 and rat mGlu2 receptors to glutamate with EC 50 values of 277 and 149 nM, respectively, without affecting the glutamate response of human mGlu3 receptor. TASP0443294 was distributed in the brain and cerebrospinal fluid after peroral administration in rats. The peroral administration of TASP0443294 inhibited methamphetamine-induced hyperlocomotion in rats, which was attenuated by an mGlu2/3 receptor antagonist, and improved social memory impairment induced by 5R,10S-(þ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801) in rats. Furthermore, TASP0443294 reduced the ketamine-induced basal gamma hyperactivity in the prefrontal cortex and suppressed rapid eye movement (REM) sleep in rats. These findings indicate that TASP0443294 is an mGlu2 receptor positive allosteric modulator with antipsychotic activity, and that the suppression of aberrant gamma oscillations and REM sleep could be considered as neurophysiological biomarkers for TASP0443294.
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Introduction
In addition to the dopamine hypothesis of schizophrenia, abnormalities in glutamatergic transmission have also been suggested to be involved in the pathophysiology of schizophrenia. Among glutamate receptors, metabotropic glutamate (mGlu) receptors, which consist of 8 subtypes (mGlu1-8), have emerged as attractive therapeutic targets for the development of novel interventions for psychiatric disorders.
Of the mGlu receptor subtypes, group II mGlu receptors, consisting of mGlu2 and mGlu3 receptors, are primarily localized presynaptically and are negatively coupled via Gi proteins to adenylate cyclase, leading to the inhibition of glutamate release upon neuronal activation (1) . In addition, mGlu2 and mGlu3 receptors are expressed postsynaptically and glial cells, respectively, where they regulate glutamate transmission (2, 3) . These receptors have been proposed to play important roles in the pathophysiology of schizophrenia (4, 5) . Indeed, several potent dual mGlu2/3 receptor agonists, which have structurally constrained analogs of glutamate, have been identified, and a growing body of evidence has shown that several mGlu2/3 receptor agonists exhibit antipsychotic activity in numerous experimental animal models of schizophrenia (4) . Among mGlu2/3 receptors, the stimulation of the mGlu2 receptor has been proposed to mediate the antipsychotic effects of mGlu2/3 receptor agonists in animal models for schizophrenia, since the antipsychotic effects of mGlu2/3 receptor agonists are no longer observed in mice lacking the mGlu2 receptor but not the mGlu3 receptor (6, 7) . These mGlu2/3 receptor agonists bind at an orthosteric binding site to which endogenous glutamate ligands bind. On the other hand, positive allosteric modulators do not activate the receptor directly, but act at an allosteric site on the receptor to potentiate glutamate-induced activation and produce their effects only in the presence of an endogenous ligand (glutamate) (8) , thereby reducing the risk of side effects and tolerance related to continuous receptor stimulation with orthosteric agonists. Therefore, allosteric modulators may offer advantages over orthosteric agonists as therapeutic agents.
In this sense, selective positive allosteric modulators of mGlu2 receptor should be of interest and may provide an advantage over orthosteric mGlu2/3 receptor agonists. Indeed, positive allosteric modulators preferentially acting on the mGlu2 receptor over the mGlu3 receptor reportedly exert antipsychotic effects in animal models (9e12). Therefore, the selective stimulation of the mGlu2 receptor may be a useful approach for the treatment of schizophrenia. However, some important differences exist in the effects of mGlu2 receptor positive allosteric modulators in animal models (10) , with these differences possibly being ascribed to the differential actions of each compound on the mGlu2 receptor. Thus, an investigation of the pharmacological profiles with structurally distinct mGlu2 receptor positive allosteric modulators should provide additional information regarding the usefulness of mGlu2 receptor positive allosteric modulators as antipsychotics. Recently, we synthesized a structurally novel and orally active mGlu2 receptor positive allosteric modulator, (2S) (Fig. 1) .
The aim of this study was to further support the assumptions that the stimulation of mGlu2 receptors results in antipsychotic effects using TASP0443294. Moreover, to evaluate the neurophysiological mechanisms of mGlu2 positive allosteric modulators, we investigated the effects of TASP0443294 on ketamine-induced basal gamma hyperactivity on electroencephalograms (EEG) showing activity in the prefrontal cortex and on rapid eye movement (REM) sleep on polysomnograms in rats.
Methods

Animals
Male SpragueeDawley and Wistar rats (purchased from Charles River, Yokohama, Japan) were used for this study. The rats were housed in a controlled animal room (room temperature: 23 ± 3 C, humidity: 50 ± 20%) with a 12-h lightedark cycle (lights on: 07:00e19:00). Rats were maintained in groups of 2 or 4 rats per cage. Food and water were available ad libitum. All the studies were conducted in accordance with the criteria of the Taisho Chinese hamster ovary (CHO) cell lines stably expressing rat mGlu2 receptor were kindly donated by Dr. Nakanishi (Kyoto University, Kyoto, Japan). CHO cell lines stably expressing human mGlu receptors (mGlu2, mGlu3 and mGlu8 receptor) were established in house. The cells expressing mGlu2 or mGlu3 receptor were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% dialyzed fetal bovine serum (FBS), 2 mM L-glutamine, 1% proline, penicillin (50 units/mL for rat mGlu2 receptor, 100 units/mL for human mGlu2 and mGlu3 receptor expressed cells) and streptomycin (50 mg/mL for rat mGlu2 receptor, 100 mg/mL for human mGlu2 and mGlu3 receptor expressed cells), 1 mM sodium pyruvate, 1 mM succinic acid, 1 mM succinic acid disodium salt and hygromycin B (400 mg/mL for human mGlu2, or 300 mg/mL for human mGlu3 receptor expressed cells). The cells expressing human mGlu8 receptor were cultured in Ham's F-12 Nutrient Mixture (F-12) containing 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin and 500 mg/mL G418. The cells were in an incubator maintained at 37 C in a humidified atmosphere of 5% CO 2 . Confluent cells expressing each mGlu receptor were washed in phosphate-buffered saline, scraped, and centrifuged at 190 Â g for 5 min at 4 C. The pellet was homogenized with 20 mM HEPES buffer (pH 7.4) for mGlu2 receptor expressed cells or 20 mM HEPES buffer containing 1 mM EDTA (pH 7.4) for mGlu3 or mGlu8 receptor expressed cells, then centrifuged at 48,000 Â g for 20 min at 4 C. The pellet was washed twice and suspended with 20 mM HEPES buffer or 20 mM HEPES buffer containing 1 mM EDTA (pH 7.4) to obtain the crude membrane fraction, which was stored at À80 C.
[ 35 S]GTPgS binding assay
The above mentioned membranes were diluted in 20 mM HEPES buffer (pH 7.4), containing 1 mM EDTA (for mGlu3 and mGlu8 receptor), 100 mM NaCl, 10 mM MgCl 2 , 8.4 mM GDP, 10 mg/ mL saponin, and 0.1% BSA to yield a protein concentration of 10 (for mGlu2 and mGlu8 receptor) or 15 (for mGlu3 receptor) mg/assay. the presence of an EC 40 -equivalent concentration of glutamate at 100 nM.
Pharmacokinetics, and brain and plasma levels in rats
For the pharmacokinetic study, TASP0443294 was intravenously administered at 0.25 mg/kg to fasted male SpragueeDawley rats (7 weeks old). Then blood samples were repeatedly collected at several time points (5, 15, and 30 min and 1, 2, 4, 8, and 24 h) after the administration of TASP0443294 from the tail vein using EDTA as the anticoagulant. To evaluate the time course of the plasma levels of TASP0443294 prior to the behavioral studies, TASP0443294 was perorally administered at a dose of 3 mg/kg to male Wistar rats (7 weeks old) and blood samples were then collected at 0.5, 1, 2, and 3 h after the administration of TASP0443294 from the tail vein using EDTA. To evaluate the brain, plasma and cerebrospinal fluid (CSF) levels after the systemic administration of TASP0443294, TASP0443294 was administered at doses of 3, 10, and 30 mg/kg perorally to male Wistar rats. Then, the rats were sacrificed after collecting a blood sample at 2.5 h after TASP0443294 administration, and the CSF and brain were rapidly collected and removed, respectively. Plasma was obtained following centrifugation, was subjected to protein precipitation, and was subsequently analyzed for TASP0443294 using a liquid chromatography/tandem mass spectrometry qualified research method on an API4000 instrument (Applied Sciex, Foster City, CA, USA). The pharmacokinetic parameters were calculated using WinNonlin software (Pharsight Corporation, Mountain View, CA, USA).
Behavioral studies 2.3.1. Locomotor activity
The locomotor activity of male Wistar rats (7 weeks old) was measured using a SCANET apparatus (Melquest Ltd., Toyama, Japan) according to previously reported methods (13) . Rats were individually placed into the test chamber (47 cm width Â 28 cm length Â 30 cm height), which in turn was placed in a soundproof box, at 120 min after TASP0443294 administration. Spontaneous locomotor activity was then measured for 60 min. In the drug interaction study, the rats were individually habituated to the test chamber placed in a soundproof box for 60 min, and methamphetamine was then subcutaneously administered at a dose of 1 mg/kg; the locomotor activities were immediately recorded for 120 min. TASP0443294 was administered perorally 120 min prior to the methamphetamine administration. LY341495 was administered intraperitoneally 60 min prior to the methamphetamine administration. Under the same condition, peroral administration of clozapine at doses of 30 and 100 mg/kg significantly inhibited methamphetamine-induced locomotor and rearing hyperactivities in rats.
Social recognition test
The social recognition test was performed as described previously (14) . The behavior tests were performed in an open-topped box (47 cm width Â 28 cm length Â 30 cm height) containing sawdust. Adult male SpragueeDawley rats (9 weeks old) were used in this test because Wistar rats exhibited shorter interaction time than SpragueeDawley rats. A rat was placed in the test cage and was allowed to habituate for 30 min. Then, an unfamiliar juvenile rat (4 weeks old) was placed in the test cage with the adult rat for 5 min (the first test session). The length of time during which the adult rat exhibited exploratory behavior (sniffing, grooming, and close following) toward the juvenile rat during the test session was recorded and was defined as the first investigation duration. The juvenile was then removed from the test cage and returned to its home cage, while the adult was left in the test cage. Thirty minutes later, the same juvenile (familiar) was then placed in the test cage once again for a 5-min test session (the second test session); the length of time spent by the adult in exploring the juvenile during this test session was defined as the second investigation duration. Observers who were blinded to the treatment group scored the investigation duration (the first and the second test sessions). The social memory for each adult rat was defined by determining the ratio of the second investigation duration to the first investigation duration. MK-801 was administered intraperitoneally to the adult rats 30 min prior to the first exposure to the juvenile. TASP0443294 was administered perorally to the rats at 120 min prior to the MK-801 administration. Under the same condition, intraperitoneal administration of clozapine at a dose of 0.3 mg/kg but not haloperidol significantly improved MK-801-induced social memory deficits in rats (14).
Quantitative electroencephalogram and polysomnogram studies 2.4.1. Implantation of electrodes
To implant the electrodes for the quantitative electroencephalogram (qEEG) or polysomnogram recording, male SpragueeDawley rats (9e10 weeks old) were anaesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally) and fixed in a stereotaxic frame. After drilling holes in the skull, stainless steel screw electrodes (E363/20; PlasticsOne, Roanoke, VA, USA) were placed on the cerebral dura mater at positions according to a rat brain atlas (15) as follows: the recording electrode was placed over the frontal cortex at 1.5 mm anterior and 2.0 mm lateral from the bregma, the reference electrode was placed over the cerebellum at 11.5 mm posterior and 0 mm lateral from the bregma, and the ground electrode was placed over the contralateral occipital cortex at 6.0 mm posterior and 2.0 mm lateral from the bregma. For the polysomnogram recording, two stainless steel subcutaneous electrodes (E363/76; PlasticsOne, Roanoke, VA, USA) with needles were bipolarly implanted into the dorsal neck region to record the electromyogram (EMG). All the electrodes were socketed into an electrode pedestal (MS363; PlasticsOne, Roanoke, VA, USA), which was then fixed to the skull using a combination of dental acrylic resin and alpha-cyanoacrylate adhesive. The electrode-implanted rats were then singly housed and allowed to recover for more than 5 days before the qEEG or polysomnogram recordings.
EEG recording for measurement of gamma band oscillation power
The qEEG recording was performed as described previously (16) . Cortical EEG recordings and drug administrations were performed under freely moving and unrestrained conditions. Rats were individually transferred to an acrylic chamber (30 cm width Â 30 cm length Â 35 cm height) placed within an electrically shielded sound-proof box and were tethered to a lead wire connected to a slip-ring commutator (SPM-15-6P; Hikari Denshi, Tokyo, Japan). The EEG signals were amplified (20,000 times) and bandpassfiltered (0.5e1000 Hz) using a biophysical amplifier (AB-611J; Nihon Kohden, Tokyo, Japan), digitized at a sampling rate of 2.5 kHz with an analog-to-digital converter (AD16-16U(PCI)EH; Contec, Osaka, Japan), and recorded using the data acquisition program VitalRecorder ® (Ver. 1.3; Kissei Comtec, Matsumoto, Japan). After a baseline EEG recording for 30 min in parallel with the acclimation of the animal to the measurement environment, TASP0443294 or the vehicle was orally administered, followed 120 min later by the subcutaneous administration of ketamine at a dose of 5 mg/kg. The EEG recording was continued for 120 min after the administration of ketamine. The animals were repeatedly used for the EEG recordings a maximum of three times after a more than 7-day interval to ensure drug washout. The EEG data were individually analyzed off-line with the data analysis program SleepSign ® (Ver. 3.0; Kissei Comtec, Matsumoto, Japan). After digital filtering (0.5e200 Hz bandpass), a fast Fourier transformation was performed for each 4-s epoch for a power spectrum analysis. The total power in the gamma band frequency (30e80 Hz) was averaged for 1-min bins and was normalized with the mean value of the 30-min baseline recordings to plot the time course. The area under the curve (AUC) for the gamma power change for 120 min after the administration of TASP0443294 and for 60 min after the ketamine injection were calculated to evaluate the effects of TASP0443294 on the baseline gamma power and the ketamine-increased gamma power, respectively. Under the same condition, subcutaneous administration of LY379268 at a dose of 1 mg/kg significantly inhibited ketamine-induced gamma hyperactivities in rats (16).
Polysomnogram recordings for the determination of sleep stage
The polysomnogram recordings were performed in the same recording environment as the above qEEG recordings. Rats were acclimated to the measurement environment under freely moving and unrestrained conditions (lighting period: 07:00 to 19:00, free access to food and water) for 16e19 h before drug administration. The polysomnogram (cortical EEG and EMG) was recorded from 06:00 to 15:00 on the administration day. TASP0443294 was perorally administered between 10:50 and 11:00. The EEG and EMG signals were amplified (20,000 times) and band-passed (EEG, 0.5e30 Hz; EMG, 15e1000 Hz) using a biophysical amplifier (AB-611J; Nihon Kohden, Tokyo, Japan), digitized at a sampling rate of 1024 Hz with an analog-to-digital converter (AD16-16U(PCI)EH; Contec, Osaka, Japan), and recorded using the data acquisition program VitalRecorder ® (Ver. 1.3; Kissei Comtec, Matsumoto, Japan). The animals were repeatedly used for the polysomnogram recording a maximum of three times after a more than 7-day interval to ensure drug washout. The polysomnogram was analyzed off-line using the data analysis program SleepSign ® (Ver. 3.0; Kissei Comtec, Matsumoto, Japan). The sleepewake states were classified in each 8-s epoch as wakefulness, non-rapid eye movement (NREM) sleep, and REM sleep by a visual verification based on the EEG and EMG patterns according to a previous report (17) . Each state was characterized as follows: wakefulness, high EMG amplitude and low EEG amplitude; NREM sleep, low EMG amplitude and high EEG amplitude with a high-power density in the delta band (0.5e4.0 Hz); REM sleep, very low EMG amplitude and low EEG amplitude with high values in the theta band (4.0e8.0 Hz). The cumulative period of REM sleep during 2 h after the drug administration was calculated and was presented as a percentage of all the states. Under the same condition, peroral administration of paroxetine at a dose of 3 mg/kg significantly decreased the duration of REM sleep in rats.
Drugs
TASP0443294 was synthesized at Taisho Chemistry Laboratories. Methamphetamine hydrochloride (methamphetamine) was purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). [ 35 S]GTPgS (specific radioactivity: 46.25 TBq/mmol) was purchased from PerkinElmer Life Science (Boston, MA, USA). MK-801 hydrogen maleate (MK-801) was purchased from SigmaeAldrich (St. Louis, MO, USA). Ketamine was purchased as veterinary Ketalar ® 50 from Sankyo Yell Pharmaceutical Co., Ltd. (Tokyo, Japan). LY341495 was purchased from Tocris Bioscience (Bristol, UK). TASP0443294 was suspended in 0.5% methylcellulose for peroral administration for the in vivo studies and was dissolved in polyethylene glycol 400 for intravenous administration in the pharmacokinetic study. Methamphetamine and MK-801 were dissolved in saline for subcutaneous and intraperitoneal administration, respectively. Ketamine was diluted in saline for subcutaneous administration. LY341495 was dissolved in 66.6 mM phosphate buffer (pH 8.0) for intraperitoneal administration. The volume of administration was 2 mL/kg. The dose selections for all the drugs were based on previous reports (14,16) and our preliminary studies.
Data analysis
For the in vitro experiments, data analyses were performed using GraphPad Prism 5 from GraphPad Software Inc. (San Diego, CA, USA). The concentrationeeffect curves for [ 35 S]GTPgS binding were fitted using nonlinear regression analysis. All the statistical analyses were performed using SAS software (SAS Institute Japan, Tokyo, Japan). The effects of TASP0443294 on the time course plot were analyzed using a two-way repeated-measures analysis of variance (ANOVA). Data were analyzed using the Student's t-test, or a one-way ANOVA followed by Dunnett's test and TukeyeKramer test. A value of P < 0.05 was regarded as significant.
Results
In vitro profiles of TASP0443294
Glutamate produced an increase in [ Fig. 2A, B and Table 1 ). The maximal responses in human and rat mGlu2 receptors, compared with the response of 1 mM glutamate, were increased to 102% and 132% upon the addition of TASP0443294, respectively (Table 1) . Of note, TASP0443294 enhanced the response induced by glutamate, shifting the glutamate concentration response curve both upward and leftward (Fig. 2C) 
Pharmacokinetic study in rats
The results of the pharmacokinetic study, including the plasma concentrations after the intravenous administration of TASP0443294 in rats, are shown in Fig. 3 . TASP0443294 had a 1.3 ± 0.1 h half-life, with a volume of distribution of 1.18 ± 0.04 L/kg and a plasma clearance of 0.64 ± 0.05 L/h/kg. The plasma concentrations of TASP0443294 at 0.5, 1, 2, and 3 h after the peroral administration of TASP0443294 are shown in Table 2A . The T max was observed at 2 h after the administration of TASP0443294. Therefore, for the in vivo study, TASP0443294 was perorally administered 2 h prior to the test. The plasma, brain and CSF concentrations of TASP0443294 at 2.5 h after the peroral administration of TASP0443294 at doses of 3, 10, and 30 mg/kg in rats are shown in Table 2B . In rats, the plasma, brain and CSF concentrations of TASP0443294 increased in a dose-dependent fashion.
Spontaneous and methamphetamine-induced locomotor and rearing activities in rats
Subcutaneous administration of methamphetamine at a dose of 1 mg/kg significantly increased locomotor (all P < 0.01) (Figs. 4A, 5A and 5B) and rearing (all P < 0.01) (Figs. 4C, 5C and 5D) activities. TASP0443294 at doses of 30 and 100 mg/kg significantly inhibited the locomotor [F(3,28) ¼ 3.97, P < 0.05] (P < 0.01) (Fig. 4A) , [F(2,27) ¼ 5.49, P < 0.01] (P < 0.05) (Fig. 5A ) and rearing [F(3,28) ¼ 3.94, P < 0.05] (P < 0.05) (Fig. 4C) , [F(2,27) ¼ 10.25, P < 0.01] (P < 0.01) (Fig. 5C ) activities elicited by the subcutaneous administration of methamphetamine. In contrast, TASP0443294 did not affect spontaneous locomotor and rearing activities up to a dose of 100 mg/kg [F(3,28) ¼ 1.7, P > 0.05] (Fig. 4B) and [F(3,28) ¼ 0.67, P > 0.05] (Fig. 4D) . In addition, pretreatment with the mGlu2/3 receptor antagonist LY341495 at a dose of 3 mg/kg significantly blocked the effect of TASP0443294 on methamphetamine-induced locomotor [F(2,27) ¼ 5.49, P < 0.01] (P < 0.05) (Fig. 5A ) and rearing [F(2,27) ¼ 10.25, P < 0.01] (P < 0.05) (Fig. 5C ) hyperactivities, indicating that the stimulation of the mGlu2 receptor mediates the effect of TASP0443294 on locomotor and rearing activities. Of note, LY341495 did not affect methamphetamine-induced locomotor and rearing hyperactivities at the doses used in the present study [F(2,21) ¼ 0.08, P > 0.05] (Fig. 5B ) and [F(2,21) ¼ 0.12, P > 0.05] (Fig. 5D ).
MK-801-induced social memory deficits in rats
The intraperitoneal administration of MK-801 at a dose of 0.1 mg/kg significantly increased the ratio of investigation duration (P < 0.01) (Fig. 6 ), indicating that MK-801 impaired short-term social memory. TASP0443294 at a dose of 30 mg/kg significantly Glutamate is used at its EC 20 and EC 40 concentrations for mGlu2 and mGlu3 receptor, respectively. Values are an average of 3 experiments. Numbers in parentheses indicated 95% confidence intervals. inhibited the increase in ratio of investigation duration elicited by MK-801 [F(2,52) ¼ 4.44, P < 0.05) (P < 0.01) (Fig. 6 ).
Ketamine-induced gamma hyperactivities in the prefrontal cortex of rats
In the time course analyses, a two-way repeated measures ANOVA demonstrated that TASP0443294 (10e30 mg/kg) showed significant doseetime interactions [F(478,5019) ¼ 1.24, P < 0.01] on the ketamine-increased gamma power (Fig. 7A ). TASP0443294 at a dose of 30 mg/kg significantly inhibited the ketamine-increased gamma power (P < 0.05) (Fig. 7B ).
REM sleep in rats
TASP0443294 decreased the duration of REM sleep during 2-h period, compared with the vehicle, in a dose-dependent fashion [F(2,30) ¼ 6.46, P < 0.05]. The effect of TASP0443294 was statistically significant at a dose of 10 mg/kg (P < 0.01) (Fig. 8) .
Discussion
In this study, we demonstrated that an orally active mGlu2 receptor positive allosteric modulator, TASP0443294, improved methamphetamine-induced hyperlocomotion and MK-801-induced social memory deficits. Moreover, TASP0443294 attenuated ketamine-induced basal gamma hyperactivity in the prefrontal cortex and decreased the duration of REM sleep. The present results not only confirm the previous findings that mGlu2 receptor positive allosteric modulators exert antipsychotic effects in animal models, but show that mGlu2 receptor positive allosteric modulators can improve the same neural circuit deficits in the same manner as orthosteric mGlu2/3 receptor agonists.
Regarding the glutamate-induced increase in [
35 S]GTPgS binding, TASP0443294 exerted similar potentiated activities and a maximal response for human and rat mGlu2 receptors, with EC 50 Table 2 Brain and plasma concentrations of TASP0443294 in rats after peroral administration. A: Pharmacokinetic profiles of TASP0443294 after peroral administration. B: Brain, plasma and CSF concentrations 2.5 h after administration of TASP0443294. These findings suggested that TASP0443294 is a selective positive allosteric modulator at the mGlu2 receptor among group II mGlu receptors. Moreover, pharmacokinetic studies revealed that TASP0443294 penetrated into the brain and CSF in quantities sufficient to exert pharmacological effects after peroral administration. Therefore, TASP0443294 might be a useful pharmacological tool for studying the function of mGlu2 receptors in vivo.
The antipsychotic effects of TASP0443294 were evaluated using two animal models of schizophrenia, methamphetamine-induced locomotor hyperactivity and MK-801-impaired social memory. Psychostimulant-induced hyperlocomotion is considered to be an animal model for the positive symptoms of schizophrenia (18) , while the induction of social memory impairment by a noncompetitive NMDA receptor antagonist, MK-801, in rats is considered to be useful as an animal model for evaluating improvements in cognitive dysfunction in schizophrenia (14) . In the present study, TASP0443294 reversed methamphetamine-induced locomotor hyperactivity and improved MK-801-induced social memory impairment in rats. These results further support our previous findings and those of others that both mGlu2/3 receptor agonists and mGlu2 receptor positive allosteric modulators are effective in these models (9, 11, 19) . However, some discrepancies exist among mGlu2 receptor positive allosteric modulators. For example, an mGlu2 receptor positive allosteric modulator, LY487379, attenuated amphetamine-induced locomotor hyperactivity as well as spontaneous locomotor activity in mice (9), while TASP0443294 did not affect spontaneous locomotor activity. Moreover, another mGlu2 receptor positive allosteric modulator, 3'-[[(2-cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-yl)oxy]methyl]-[1,1'-biphenyl]-4-carboxylic acid (BINA), reportedly did not reverse amphetamine-induced hyperlocomotion (10) . Although these differences may be ascribed to differences in the mode of potentiation and modest intrinsic agonist activity at the mGlu2 receptor, the reason for these differences among mGlu2 receptor allosteric modulators remains unclear. Different classes of positive allosteric modulators may have different in vivo effects as a result of differential actions on receptors (10, 20) . Thus, TASP0443294, which is structurally distinct from LY487379 and BINA, may be useful for delineating the molecular mechanisms of the above-mentioned differences among mGlu2 receptor positive allosteric modulators. Of note, the effect of TASP0443294 on methamphetamine-induced locomotor hyperactivity is not an off-target effect, but rather mediates the stimulation of the mGlu2 receptor, since the effect of TASP0443294 was completely blocked by an mGlu2/3 receptor antagonist, LY341495, at a dose that did not affect methamphetamine-induced locomotor hyperactivity by itself. However, in addition to the mGlu2/3 receptor, LY341495 also has antagonistic activities at the mGlu7 and mGlu8 receptors (21).
Because we have not yet tested the activity of TASP0443294 at the mGlu7 receptor, a possible role of the mGlu7 receptor in the in vivo effect of TASP0443294 cannot be fully ruled out.
In the present study, the neurophysiological effects of TASP0443294 were evaluated using two EEG recordings: REM sleep and ketamine-induced gamma oscillation. EEG is considered to be a translational biomarker for targets and compounds, since EEG can be recorded in both humans and rodents. The present result that TASP0443294 reduced the amount of REM sleep in rats is consistent with previous findings that orthosteric mGlu2/3 receptor agonists and other mGlu2 receptor positive allosteric modulators, such as BINA, THIIC and JNJ-40068782, reduced the amount of REM sleep in rats (12,22e24) . Thus, REM sleep as observed on a polysomnogram may be useful as a sensitive biomarker for mGlu2 receptor activation. Glutamate levels reportedly increase during REM sleep in the orbitofrontal and cerebral cortex of rats (25, 26) . Therefore, the inhibition of glutamate release elicited by the stimulation of mGlu2 receptors may result in a decrease in the duration of REM sleep, and mGlu2 receptor positive allosteric modulators may share the same neuronal mechanisms for their effects on the reduction in REM sleep and their antipsychotic actions.
Aberrant gamma oscillations have been reported to be associated with the symptoms of schizophrenia (27, 28) . The administration of NMDA-receptor antagonists reportedly increase basal gamma oscillation on EEG recording of activity in the prefrontal cortex, presumably as a result of the disinhibition of pyramidal neurons through a reduction in g-aminobutyric acid (GABA) interneurons activities (16) , which may represent the neuronal mechanism for the glutamate hypothesis explaining schizophrenia (29) . In the present study, TASP0443294 inhibited the cortical spontaneous gamma hyperactivity elicited by ketamine in freely moving rats. In a preliminary study, TASP0443294 slightly but dose-dependently reduced the baseline of gamma oscillation power with the same effective doses (data not shown). However, TASP0443294 inhibited the trough-to-peak response of ketamine, although it was not statistically significant (data not shown). Given that the mGlu2/3 receptor agonist LY379268 inhibits both ketamine-induced increases in gamma oscillations and reduces spontaneous gamma oscillations in the cortex of rats (16, 30) , the activation of the mGlu2 receptor may play a role in the modulation of gamma oscillations. Of note, this is the first result to show that the attenuation of NMDA receptor antagonist-induced aberrant gamma oscillations by an mGlu2/3 receptor agonist is mediated through the stimulation of the mGlu2 receptor, and that mGlu2 receptor positive allosteric modulators may improve the same neuronal circuit deficits possibly observed in schizophrenia as do orthosteric mGlu2/3 receptor agonists. The hippocampus (31), amygdala (32) , and prefrontal cortex (33) are thought to be involved in social memory in rodents. Therefore, the improvement in social memory impairment induced by an mGlu2 receptor positive allosteric modulator may be partially attributable to the suppression of the aberrant excitability of pyramidal neurons through GABAergic disinhibition, at least in the prefrontal cortex. It would be interesting to compare the effect of mGlu2 receptor positive allosteric modulators on ketamine-increased gamma oscillation and locomotor activity in future studies.
In summary, the orally active mGlu2 receptor positive allosteric modulator TASP0443294 exhibits antipsychotic-like activities in animal models. TASP0443294 inhibited not only dopamine-related, but also NMDA receptor-related abnormal behaviors that are considered to be animal models for the positive symptoms and cognitive dysfunction of schizophrenia, respectively. Moreover, because TASP0443294 improved aberrant gamma oscillations, gamma oscillations, in addition to REM sleep, may be useful as translatable biomarkers for mGlu2 receptor positive allosteric modulators. In addition, TASP0443294 may provide a useful tool for examining the usefulness of mGlu2 receptor positive allosteric modulators for the treatment of schizophrenia as well as the neuronal mechanisms underlying the antipsychotic effects of mGlu2 receptor positive allosteric modulators.
